... San Antonio Breast Cancer Symposium. Already a GenomeWeb member? LoginLogin. Get the full story with GenomeWeb Premium. Only $95 for the first 90 ...
News
- Study Failure Spotlights Challenges for ctDNA Strategies in Breast Cancer Drug Trials
- RemeGen reports Phase III success for disitamab vedotin | Biotechnology | The Pharmaletter
16 December 2024. More on this story... UCB and Biogen's dapirolizumab pegol paves new path for SLE treatment · Biotechnology.
- Shareholders do not share Bicycle cheer | The Pharmaletter
... Biotechnology. 16 December 2024. More on this story... Novartis extends radiopharma lead with new collab · Pharmaceutical.
- Two startups nab $50K in San Antonio holiday pitch competition
The San Antonio company launched in May and currently has 150 subscribers for its services. ... biotechnology research and development.
- Ibrance Plus Frontline Standard Therapy Delays Progression by 15 Months in HER2, HR ...
SAN ANTONIO – Pfizer's CDK4/6 inhibitor Ibrance (palbociclib) added to ... Biotech · Leapfrog Bio to Begin Phase II Trial of Synthetic Lethal ...